BG105302A - Means for improving cognition - Google Patents
Means for improving cognitionInfo
- Publication number
- BG105302A BG105302A BG105302A BG10530201A BG105302A BG 105302 A BG105302 A BG 105302A BG 105302 A BG105302 A BG 105302A BG 10530201 A BG10530201 A BG 10530201A BG 105302 A BG105302 A BG 105302A
- Authority
- BG
- Bulgaria
- Prior art keywords
- improving cognition
- acetylcholinesterase
- alzheimer
- inhibitor
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98203454 | 1998-10-16 | ||
PCT/EP1999/007804 WO2000023057A2 (en) | 1998-10-16 | 1999-10-12 | Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
Publications (1)
Publication Number | Publication Date |
---|---|
BG105302A true BG105302A (en) | 2001-11-30 |
Family
ID=8234219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG105302A BG105302A (en) | 1998-10-16 | 2001-03-01 | Means for improving cognition |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1121131A2 (ko) |
JP (1) | JP2002527469A (ko) |
KR (1) | KR20010072878A (ko) |
CN (1) | CN1367697A (ko) |
AU (1) | AU6472799A (ko) |
BG (1) | BG105302A (ko) |
BR (1) | BR9914419A (ko) |
CA (1) | CA2345767A1 (ko) |
EE (1) | EE200100136A (ko) |
HK (1) | HK1039745A1 (ko) |
HR (1) | HRP20010262A2 (ko) |
HU (1) | HUP0103781A3 (ko) |
ID (1) | ID28441A (ko) |
IL (1) | IL142588A0 (ko) |
NO (1) | NO20011403L (ko) |
PL (1) | PL348107A1 (ko) |
SK (1) | SK4592001A3 (ko) |
TR (1) | TR200101082T2 (ko) |
WO (1) | WO2000023057A2 (ko) |
ZA (1) | ZA200103081B (ko) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102841D0 (en) * | 2001-02-05 | 2001-03-21 | Novartis Ag | Organic compounds |
AU2006201188B2 (en) * | 2001-02-05 | 2007-11-15 | Novartis Ag | New use of iloperidone |
WO2003037337A1 (en) * | 2001-10-30 | 2003-05-08 | Novartis Ag | Depot formulations of iloperidone and a star polymer |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
US20040192754A1 (en) * | 2003-03-24 | 2004-09-30 | Shapira Nathan Andrew | Methods for treating idiopathic hyperhidrosis and associated conditions |
TW200501962A (en) * | 2003-04-01 | 2005-01-16 | Novartis Ag | Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
JP2008523058A (ja) * | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
MX2009009234A (es) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | Uso nuevo de inhibidores de ciclasa de glutaminilo. |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
MX2007008642A (es) * | 2007-07-16 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias. |
CN102905532A (zh) | 2010-02-09 | 2013-01-30 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
EP0515301A3 (en) * | 1991-05-14 | 1993-06-16 | Ernir Snorrason | Improvements in benzodiazepine treatment by cholinesterterase inhibitors |
JP4640888B2 (ja) * | 1997-08-11 | 2011-03-02 | ザ ユニヴァーシティー オブ サウス フロリダ | 神経精神性疾患用ニコチンアンタゴニスト |
RU2219924C2 (ru) * | 1998-04-14 | 2003-12-27 | Дзе Дженерал Хоспитал Корпорейшн | Способ лечения нейропсихиатрических расстройств |
-
1999
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/ko not_active Application Discontinuation
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/ja not_active Withdrawn
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/sk unknown
- 1999-10-12 CN CN99812184A patent/CN1367697A/zh active Pending
- 1999-10-12 ID IDW20010828A patent/ID28441A/id unknown
- 1999-10-12 PL PL99348107A patent/PL348107A1/xx unknown
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 EE EEP200100136A patent/EE200100136A/xx unknown
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/hu unknown
- 1999-10-12 IL IL14258899A patent/IL142588A0/xx unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/xx unknown
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/pt not_active IP Right Cessation
-
2001
- 2001-03-01 BG BG105302A patent/BG105302A/xx unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/no not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/hr not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
-
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1121131A2 (en) | 2001-08-08 |
PL348107A1 (en) | 2002-05-06 |
SK4592001A3 (en) | 2001-12-03 |
BR9914419A (pt) | 2001-06-26 |
EE200100136A (et) | 2002-06-17 |
TR200101082T2 (tr) | 2001-09-21 |
HRP20010262A2 (en) | 2002-06-30 |
CA2345767A1 (en) | 2000-04-27 |
ID28441A (id) | 2001-05-24 |
WO2000023057A3 (en) | 2000-07-27 |
AU6472799A (en) | 2000-05-08 |
HUP0103781A2 (hu) | 2002-03-28 |
IL142588A0 (en) | 2002-03-10 |
KR20010072878A (ko) | 2001-07-31 |
CN1367697A (zh) | 2002-09-04 |
HK1039745A1 (zh) | 2002-05-10 |
NO20011403D0 (no) | 2001-03-20 |
JP2002527469A (ja) | 2002-08-27 |
ZA200103081B (en) | 2002-07-12 |
NO20011403L (no) | 2001-03-20 |
WO2000023057A2 (en) | 2000-04-27 |
HUP0103781A3 (en) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG105302A (en) | Means for improving cognition | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
SI1509232T1 (sl) | Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
BR0008059A (pt) | Composições de valdecoxib | |
HK1029043A1 (en) | Remedy for neurodegenerative diseases. | |
NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
HU9603042D0 (en) | Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration | |
AU2002307049A1 (en) | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia | |
ATE240115T1 (de) | Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose | |
BG105256A (en) | Muscarinic agonists and antagonists | |
IL149134A0 (en) | Pharmaceutical compositions containing tofisopam | |
IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
IL159241A0 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
AU4568400A (en) | Sphingomyelinase inhibitor | |
RS60604A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
GEP20043377B (en) | Pharmaceutical Complex | |
BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
IL129267A (en) | Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence |